These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

317 related items for PubMed ID: 12909504

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Modulation of folliculogenesis and steroidogenesis in women by graded menotrophin administration.
    Filicori M, Cognigni GE, Pocognoli P, Tabarelli C, Spettoli D, Taraborrelli S, Ciampaglia W.
    Hum Reprod; 2002 Aug; 17(8):2009-15. PubMed ID: 12151429
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of low-dose human chorionic gonadotropin alone to complete controlled ovarian stimulation.
    Filicori M, Cognigni GE, Gamberini E, Parmegiani L, Troilo E, Roset B.
    Fertil Steril; 2005 Aug; 84(2):394-401. PubMed ID: 16084880
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Is earlier administration of human chorionic gonadotropin (hCG) associated with the probability of pregnancy in cycles stimulated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone (GnRH) antagonists? A prospective randomized trial.
    Kyrou D, Kolibianakis EM, Fatemi HM, Tarlatzis BC, Tournaye H, Devroey P.
    Fertil Steril; 2011 Nov; 96(5):1112-5. PubMed ID: 21924414
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Successful pregnancies in patients with estrogenic anovulation after low-dose human chorionic gonadotropin therapy alone following hMG for controlled ovarian hyperstimulation.
    Lee KL, Couchman GM, Walmer DK.
    J Assist Reprod Genet; 2005 Jan; 22(1):37-40. PubMed ID: 15807221
    [Abstract] [Full Text] [Related]

  • 10. Implications of using follicle-stimulating hormone preparations depleted of luteinizing hormone to achieve follicular growth in in vitro fertilization.
    Agrawal R, Conway GS, Engmann L, Bekir JS, Jacobs HS.
    Gynecol Endocrinol; 1998 Feb; 12(1):9-15. PubMed ID: 9526704
    [Abstract] [Full Text] [Related]

  • 11. Effect of letrozole at 2.5 mg or 5.0 mg/day on ovarian stimulation with gonadotropins in women undergoing intrauterine insemination.
    Noriega-Portella L, Noriega-Hoces L, Delgado A, Rubio J, Gonzales-Castañeda C, Gonzales GF.
    Fertil Steril; 2008 Nov; 90(5):1818-25. PubMed ID: 18083169
    [Abstract] [Full Text] [Related]

  • 12. Induction of multiple follicular development by a single dose of long-acting recombinant follicle-Stimulating hormone (FSH-CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization.
    Devroey P, Fauser BC, Platteau P, Beckers NG, Dhont M, Mannaerts BM.
    J Clin Endocrinol Metab; 2004 May; 89(5):2062-70. PubMed ID: 15126522
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Differing response to GnRH antagonists in cycles of ovarian hyperstimulation plus intrauterine insemination].
    Barros-Delgadillo JC, Trejo-Castañeda H, E-Ormsby C, Gaviño-Gaviño F.
    Ginecol Obstet Mex; 2010 Jan; 78(1):15-28. PubMed ID: 20931799
    [Abstract] [Full Text] [Related]

  • 15. A comparison of outcomes from in vitro fertilization cycles stimulated with either recombinant luteinizing hormone (LH) or human chorionic gonadotropin acting as an LH analogue delivered as human menopausal gonadotropins, in subjects with good or poor ovarian reserve: a retrospective analysis.
    Dahan MH, Agdi M, Shehata F, Son W, Tan SL.
    Eur J Obstet Gynecol Reprod Biol; 2014 Jan; 172():70-3. PubMed ID: 24314801
    [Abstract] [Full Text] [Related]

  • 16. Adding human menopausal gonadotrophin to antagonist protocols - is there a benefit?
    Martin-Johnston M, Beltsos AN, Grotjan HE, Uhler ML.
    Reprod Biomed Online; 2007 Aug; 15(2):161-8. PubMed ID: 17697491
    [Abstract] [Full Text] [Related]

  • 17. Advantages of recombinant follicle-stimulating hormone over human menopausal gonadotropin for ovarian stimulation in intrauterine insemination: a randomized clinical trial in unexplained infertility.
    Rashidi M, Aaleyasin A, Aghahosseini M, Loloi S, Kokab A, Najmi Z.
    Eur J Obstet Gynecol Reprod Biol; 2013 Jul; 169(2):244-7. PubMed ID: 23541417
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effectiveness of human menopausal gonadotropin versus recombinant follicle-stimulating hormone for controlled ovarian hyperstimulation in assisted reproductive cycles: a meta-analysis.
    van Wely M, Westergaard LG, Bossuyt PM, van der Veen F.
    Fertil Steril; 2003 Nov; 80(5):1086-93. PubMed ID: 14607553
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.